Fig. 6. Suppressing FA uptake promotes the efficacy of conventional chemotherapies.
a Synergy analyses in MNA (LAN5 and IMR32) and non-MNA (SHEP) cells treated with CB5 (0.4–2.5 µM), VP16 (5–50 nM) and their combination for 72 h. Heatmap represents mean Bliss scores from three independent experiments. Bliss score > 10 indicates synergy. b Cell viability and Caspase 3/7 activity after single and combination treatments. Cells were treated with CTRL, CB5 (3 µM), VP16 (80 nM), or their combination for 72 h. Mean ± SD (n = 3); one-way ANOVA with Tukey’s multiple comparisons test. c Anti-tumor activity of CB5 + VP16 combination therapy in LAN5-derived orthotopic xenografts. LAN5 cells were implanted in the renal capsule of NCr nude mice. Two weeks after implantation, mice were treated with CTRL (vehicle), CB5 (15 mg/kg, b.i.d. 6 days/week), VP16 (8 mg/kg daily, 3 days/week) or their combination for 2 weeks. Tumor weights after 2 weeks of treatment are shown. Mean ± SEM (CTRL = 11, CB5 = 11, VP16 = 10, CB5 + VP16 = 12); two-sided unpaired Mann–Whitney test. d Survival analysis in patient-derived orthotopic xenografts. Cells prepared from one MNA patient tumor (P8) were implanted in the renal capsule of NCr nude mice. Five and half weeks after implantation, mice were treated with CTRL (vehicle), CB5 (15 mg/kg, b.i.d. 6 days/week), VP16 (6 mg/kg daily, 3 days/week), or their combination for 5 weeks. Survival was plotted as a Kaplan–Meier curve and analyzed by the log-rank test (CTRL = 12, CB5 = 10, VP16 = 10, CB5 + VP16 = 11). Px treatment period; FC fold change. Source data are provided in the Source Data file.